Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Gillard

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
European Journal of Pharmacology|January 4, 2006
Changes in pH differently affect the binding properties of histamine H1 receptor antagonistsMichel Gillard, Pierre Chatelain
Epilepsia|December 25, 2016
Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A proteinMartyn D Wood, Michel Gillard
European Journal of Pharmacology|March 25, 2006
Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant proteinMichel Gillard, Pierre Chatelain, Bruno Fuks
Allergy and Asthma Proceedings|April 2, 2009
The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistaminesSherwin Gillman, Michel Gillard, Margherita Strolin Benedetti
British Journal of Pharmacology|October 24, 2014
Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptorsMartyn Wood, Vanessa Dubois, Dieter Scheller, et al.
European Journal of Pharmacology|July 16, 2005
[3H]linopirdine binding to rat brain membranes is not relevant for M-channel interactionChristian Wolff, Michel Gillard, Bruno Fuks, et al.
European Journal of Pharmacology|May 18, 2011
Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant propertiesMichel Gillard, Bruno Fuks, Karine Leclercq, et al.
Epilepsia|August 26, 2018
Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A proteinMartyn D Wood, Zara A Sands, Catherine Vandenplas, et al.
European Journal of Pharmacology|August 30, 2005
Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cordNathalie Lambeng, Michel Gillard, Pascale Vertongen, et al.
European Journal of Pharmacology|October 14, 2003
Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brainMichel Gillard, Bruno Fuks, Philippe Michel, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
European Journal of Pharmacology|January 4, 2006
Changes in pH differently affect the binding properties of histamine H1 receptor antagonistsMichel Gillard, Pierre Chatelain
Epilepsia|December 25, 2016
Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A proteinMartyn D Wood, Michel Gillard
European Journal of Pharmacology|March 25, 2006
Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant proteinMichel Gillard, Pierre Chatelain, Bruno Fuks
Allergy and Asthma Proceedings|April 2, 2009
The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistaminesSherwin Gillman, Michel Gillard, Margherita Strolin Benedetti
British Journal of Pharmacology|October 24, 2014
Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptorsMartyn Wood, Vanessa Dubois, Dieter Scheller, et al.
European Journal of Pharmacology|July 16, 2005
[3H]linopirdine binding to rat brain membranes is not relevant for M-channel interactionChristian Wolff, Michel Gillard, Bruno Fuks, et al.
European Journal of Pharmacology|May 18, 2011
Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant propertiesMichel Gillard, Bruno Fuks, Karine Leclercq, et al.
Epilepsia|August 26, 2018
Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A proteinMartyn D Wood, Zara A Sands, Catherine Vandenplas, et al.
European Journal of Pharmacology|August 30, 2005
Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cordNathalie Lambeng, Michel Gillard, Pascale Vertongen, et al.
European Journal of Pharmacology|October 14, 2003
Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brainMichel Gillard, Bruno Fuks, Philippe Michel, et al.
Pageof 6